Dabigatran Etexilate and Clopidogrel: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Clopidogrel
Dabigatran Etexilate
No brand names on record
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
An increased risk of bleeding
Interaction Deep Dive
Concomitant use of dabigatran and clopidogrel may increase the risk of bleeding14. Additionally, coadministration of dabigatran with other drugs that affect hemostasis (such as clopidogrel) may increase the risk of epidural or spinal hematomas, which may result in long-term or permanent paralysis, in patients receiving neuraxial anesthesia or undergoing spinal puncture. Promptly evaluate signs or symptoms of blood loss (eg, drop in hemoglobin and/or hematocrit or hypotension) and discontinue use of dabigatran in patients with active pathological bleeding 1.
Why it happens (mechanism)
Additive effects on hemostasis
Literature reports
3 reports — tap to read
a) In clinical studies exploring P-gp and other pathways, dabigatran did not meaningfully alter the pharmacokinetics of clopidogrel 1.
b) Concomitant use of direct oral anticoagulant (DOAC) and antiplatelet therapy (APT; n=78) compared to DOAC therapy alone (n=329) did not significantly alter the incidence of major bleeding (1.3% vs 1.2%) or clinically relevant non-major bleeding (10.2% vs 6.4%) over 6 months of treatment in a retrospective study. Patients were primarily Caucasian men with a mean age of 63.7 years. Patients receiving concurrent APT had significantly higher mean body mass index (30.7 vs 28.4), mean CHA2DS2-VASc score (4.28 vs 3.85), and were more likely to have diabetes (26.9% vs 17.3%) compared with those prescribed DOAC monotherapy. DOACs were prescribed for VTE treatment or atrial fibrillation, and included apixaban (58.5%), rivaroxaban (38.1%), and dabigatran (3.4%). Single antiplatelet therapy was utilized in 94.9% (74 patients), with aspirin 81 mg once daily as the most common regimen (69 patients). Other APT regimens included aspirin 81 mg twice daily (3 patients), aspirin 325 mg daily (1 patient), clopidogrel 75 mg daily (1 patient), and dual APT with aspirin 81 mg and clopidogrel 75 mg daily (4 patients) 2.
c) In a retrospective study of patients 65 years or older who received a coronary artery stent (N=70,900), coadministration of direct oral anticoagulant (DOAC; dabigatran or rivaroxaban) and prescription antiplatelet therapy (predominantly clopidogrel) significantly increased the risk of major hemorrhagic events compared with antiplatelet therapy alone (HR, 2.36; 95% CI, 1.91 to 2.93) over 12 months following stent placement; this risk was similar to coadministration of warfarin and antiplatelets (HR, 2; 95% CI, 1.83 to 2.18). When patients were stratified by index atrial fibrillation (AF) status, the risk of major hemorrhagic events was also significantly increased with coadministration of DOAC and antiplatelet therapy for both AF (HR, 1.94; 95% CI, 1.48 to 2.54; n=10,238) and non-AF groups (HR, 3.09; 95% CI, 2.15 to 4.46; n=60,662). Hemorrhages in the first 30 days after stenting were considered periprocedural morbidity and excluded. The average observation period was 11.5 months, with 24.470,270 person-days of exposure; antiplatelet only therapy accounted for 73.8% of person-days of exposure, antiplatelets plus DOACs for 0.6%, and antiplatelets plus warfarin for 4.7% 3.
Common questions
Can I take Dabigatran Etexilate and Clopidogrel together?
An increased risk of bleeding Always confirm with your pharmacist or prescriber before making any change.
How serious is the Dabigatran Etexilate and Clopidogrel interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "established". Well documented — supported by controlled studies or strong clinical data.
From our Q&A
Real reader questions about these medications, each personally answered by our pharmacist:
Questions for your pharmacist
- Does my dose of Dabigatran Etexilate or Clopidogrel need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (4)
- Product Information: PRADAXA(R) oral capsules, dabigatran etexilate oral capsules. Boehringer Ingelheim Pharmaceuticals Inc (per FDA), Ridgefield, CT, 2023. DailyMed
- Tinkham TT, Vazquez SR, Jones AE, et al: Direct oral anticoagulant plus antiplatelet therapy: prescribing practices and bleeding outcomes. J Thromb Thrombolysis 2020; 49(3):492-496. PubMed
- Bekelis K, Chang CH, Malenka D, et al: Direct oral anticoagulant and antiplatelet combination therapy: hemorrhagic events in coronary artery stent recipients. J Clin Neurosci 2018; 50:24-29. PubMed
- Product Information: PLAVIX(R) oral tablets, clopidogrel bisulfate oral tablets. sanofi-aventis US LLC (per FDA), Bridgewater, NJ, 2022. DailyMed
Keep reading about Clopidogrel
Keep reading about Dabigatran Etexilate
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist